Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production
doi: 10.1016/S0140-6736(17)32129-3 2 AfshinAForouzanfarMHReitsmaMBSurP.EstepKLeeAet al
It is a growth hormone-releasing peptide and ghrelin mimetic
These hypothetical examples show how eligibility, documentation, and plan design can lead to different decisions
The ideal candidates for GLP-1 therapy during menopause are those with obesity, insulin resistance, or persistent weight gain despite healthy habits
Only patients with detectable HCV RNA should be considered for pegylated interferon alfa and ribavirin therapy and the HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure